Analysis of the Contributing Role of Drug Transport Across Biological Barriers in the Development and Treatment of Chemotherapy-induced Peripheral Neuropathy
Overview
Authors
Affiliations
Background: Chemotherapy-induced peripheral neuropathy (CIPN) represents a major unmet medical need that currently has no preventive and/or curative treatment. This is, among others, driven by a poor understanding of the contributive role of drug transport across biological barriers to target-site exposure.
Methods: Here, we systematically investigated the transport of 11 small-molecule drugs, both, associated and not with CIPN development, at conventional (dorsal root ganglia, sciatic nerve) and non-conventional (brain, spinal cord, skeletal muscle) CIPN sites. We developed a Combinatory Mapping Approach for CIPN, CMA-CIPN, combining in vivo and in vitro elements.
Results: Using CMA-CIPN, we determined the unbound tissue-to-plasma concentration ratio (K) and the unbound intracellular-to-extracellular concentration ratio (K), to quantitatively assess the extent of unbound drug transport across endothelial interfaces and parenchymal cellular barriers of investigated CIPN-sites, respectively, in a rat model. The analysis revealed that unique pharmacokinetic characteristics underly time-dependent accumulation of the CIPN-positive drugs paclitaxel and vincristine at conventional (dorsal root ganglia and sciatic nerve) and non-conventional (skeletal muscle) CIPN sites. Investigated CIPN-positive drugs displayed intracellular accumulation contrary to CIPN-negative drugs nilotinib and methotrexate, which lacked this feature in all investigated tissues.
Conclusions: Hence, high unbound drug intracellular and extracellular exposure at target sites, driven by an interplay of drug transport across the endothelial and parenchymal cellular barriers, is a predisposing factor to CIPN development for CIPN-positive drugs. Critical drug-specific features of unbound drug disposition at various CIPN- sites provide invaluable insights into understanding the pharmacological/toxicological effects at the target-sites which will inform new strategies for monitoring and treatment of CIPN.
Ballgren F, Hammarlund-Udenaes M, Loryan I Fluids Barriers CNS. 2024; 21(1):95.
PMID: 39623471 PMC: 11613587. DOI: 10.1186/s12987-024-00598-6.
Girdenyte M, Hu Y, Ginosyan A, Hammarlund-Udenaes M, Loryan I Front Pharmacol. 2024; 15:1486686.
PMID: 39568585 PMC: 11576287. DOI: 10.3389/fphar.2024.1486686.
Region-independent active CNS net uptake of marketed H/OC antiporter system substrates.
Ballgren F, Hu Y, Li S, van de Beek L, Hammarlund-Udenaes M, Loryan I Front Cell Neurosci. 2024; 18:1493644.
PMID: 39534684 PMC: 11554538. DOI: 10.3389/fncel.2024.1493644.
Svane N, Ballgren F, Ginosyan A, Kristensen M, Brodin B, Loryan I J Headache Pain. 2024; 25(1):187.
PMID: 39478486 PMC: 11523665. DOI: 10.1186/s10194-024-01894-0.